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Epigenetic changes marked by DNA methylation have been proposed to play a role in age-related disease. We investigated DNA methylation
changes in cardiovascular atherosclerotic tissues and in-vitro vascular senescence in the promoter of estrogen receptor β gene, which has essential
roles in vascular function. Coronary atherosclerotic tissues showed higher methylation levels (28.7%) than normal appearing arterial (6.7%–
10.1%) and venous tissues (18.2%). In comparing estrogen receptor β methylation between plaque and non-plaque regions in ascending aorta,
common carotid artery, and femoral artery of two patients, the plaque lesions showed consistently higher methylation levels than non-plaque
regions. Passage-dependent increased estrogen receptor β methylation was observed in three of six human aortic endothelial or smooth muscle cell
lines cultured in-vitro to vascular senescence. Estrogen receptor β expression in these vascular cell lines was significantly activated by DNA-
methyltransferase inhibition. This activity was augmented by histone deacetylase inhibition. These findings provide evidence of epigenetic
dysregulation of estrogen receptor β in atherosclerosis and vascular aging. We suggest that focal epigenetic changes in estrogen receptor β
contribute to the development of atherosclerosis and vascular aging.
© 2006 Elsevier B.V. All rights reserved.Keywords: Aging; Atherosclerosis; DNA methylation; Epigenetic dysregulation; Estrogen receptor beta; In-vitro senescence1. Introduction
Methylation of CpG rich regions in the promoter of some
genes is an epigenetic change that results in permanent
inactivation of gene transcription without associated genetic
abnormality [1]. Age-related increased promoter methylation
has been proposed as a possible epigenetic mechanism
contributing to diseases associated with the aging process
[2]. Indeed, methylation of the ERα gene and several others⁎ Corresponding author. Department of Neurology, Chungnam National
University Hospital, 640 Daesa-dong, Joong-ku, Taejon, 301-721, Korea. Tel.:
+82 42 280 7805; fax: +82 42 252 8654.
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doi:10.1016/j.bbadis.2006.10.004has been reported to occur as a direct function of
physiologic aging in normal human colonic mucosa [3].
Studies to understand the presence and consequences of age-
related methylation have mainly focused on cancer so far,
even though aging is a very important risk factor in vascular
diseases.
Cardioprotective effects of estrogen have been suggested by
in-vitro, in-vivo, and epidemiological studies [4]. The estrogen
receptors α (ERα) and β (ERβ) modulate some of the
beneficial estrogenic effects on vascular endothelial cells (EC)
and smooth muscle cells (SMC) [4]. Activation of specific
target genes by ERα has been identified in vascular EC and
SMC in women and men [4,5]. Recently, an essential role of
ERβ has been reported in the response to in-vivo vascular
injury [6]. In ERβ knockout mice, abnormal vascular function
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demonstrated [7].
A significant increase of ERα promoter area methylation
was previously reported as an epigenetic change in aging
cardiovascular tissues [8,9]. An epigenetic evaluation of ERβ in
vascular diseases has not been reported yet. In the present study,
we report significant epigenetic changes of the ERβ gene
promoter in atherosclerosis, cardiovascular tissues, and in-vitro
vascular senescence.
2. Methods
2.1. Tissue samples
Atherosclerotic samples were collected from directional coronary
atherectomy (DCA) and surgical carotid endaterectomy (CEA) samples.
Cardiovascular samples from ascending aorta (AA), internal mammary
artery (IMA), saphenous vein (SV), and right atrium (RA) were obtained
from patients during coronary artery bypass graft. We obtained vascular
tissue samples of plaque and non-plaque regions in segments of ascending
aorta (AA), common carotid artery (CCA), and femoral artery (FA) in a 54-
year-old male and a 54-year-old female. Plaque lesions having yellowish
elevation of intima were discriminated from non-plaque region by the naked
eye. Plaque and non-plaque regions were clearly separated along their
margins by dissection. The intima was gathered by peeling from the medianFig. 1. ERβ methylation in vascular samples. (A) Schematic diagram of the promote
represented by open bars. Vertical lines, each CpG site; arrow, putative transcription
type. Patient numbers are indicated above each gel. M, methylated alleles; UM, unm
SW48 colon cancer cell line (closed bars) and unmethylated human leukocyte (opene
(D) Dot plot of ERβmethylation level in different tissues. DCA (28.7%) manifests th
(11.9%), IMA (6.7%), AA (10.1%), SV (18.2%), RA (14.4%).layer of each separated regions. Structural differences between each plaque
and non-plaque segments were confirmed by light microscopy. All tissue
samples were frozen and stored at −80 °C until DNA extraction.
2.2. Methylation evaluation
To evaluate ERβ methylation levels, methylation specific polymerase chain
reaction (MSP) and combined bisulfite restriction analysis (COBRA) were
performed as previously described after the bisulfite treatment of 1 μg of
genomic DNA [10,11]. The promoter region of ERβ has a typical CpG island of
about 1 kb that contains the transcription start site (Fig. 1A). Primers were
designed based on the published ERβ promoter sequence (GeneBank Accession
No.: AF191544). In MSP, separate primers are used to amplify methylated
alleles (M) and unmethylated alleles (UM). Semi-quantitative MSP is done
by limiting PCR cycles, and quantitating the M PCR products relative to the
UM+M PCR products.
For MSP analysis, a primer set (ERB-MSP-M1, 5′TAGGAGGTAGTTG-
TAAGCGC3′ and ERB-MSP-M2, 5′ACAACTCAAACTCCGAACG3′)
amplified a 159 bp fragment from the methylated allele, and another primer
set (ERB-MSP-U1, 5′TTGTTAGGAGGTAGTTGTAAGTGT3′ and ERB-
MSP-U2, 5′CCTACAACTCAAACTCCAAACA3′) amplified an overlapping
166 bp fragments from the unmethylated allele within exon 1 of ERβ (Fig.
1A). PCR was performed using 2 μl of bisulfite-treated genomic DNA in
25 μl reaction volumes containing 1x PCR buffer [67 mM Tris–HCl (pH
8.8), 6.6 mM MgCl2, 16.6 NH4SO4, and 10 mM 2-mercaptoethanol],
1.25 mM dNTP mixture, 1 μM of each primer, and 1 unit of Taq DNA
polymerase (Invitrogen). For both primer sets, amplification was carried outr region of the ERβ gene. PCR amplification sites for the MSP primer sets are
start site; ATG, start site of the coding sequence. (B) MSP results of each vessel
ethylated alleles. (C) Semi-quantitation of ERβ MSP using heavily methylated
d bars) shows linear correlation between expected and measured methylation %.
e highest mean methylation level among cardiovascular samples (p<0.01), CEA
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30 s, 51 °C: 30 s, 72 °C: 30 s), and final extension for 5 min at 72 °C.
Fifteen μl of the PCR product were electrophoresed in 6% polyacrylamide
gels and visualized by ethidium bromide staining. The methylation level in
each sample was evaluated by densitometry, measuring the adjusted volume
percent of methylated and unmethylated band intensities (Quantity One, ver.
4.0.3, BioRad).
Methylation was confirmed by bisulfite genomic sequencing of the
amplified methylated alleles from MSP products. The amplified DNA was
cloned using the TOPO-TA Cloning Kit (Invitrogen). Plasmids from distinct
colonies were extracted (Miniprep Kit, Qiagen) and sequenced (ABI Prism 377
DNA Sequencer, Applied Biosystems).
Two COBRA primer sets were designed. The first set (COBRA I; ERB-
CBR-1; ATT GTT TTT TGA AAT TTG TA, ERB-CRB2; AAC TTA CAA
ATA AAC ACA CC) amplified a 247 bp fragment within the untranslated
exon 1 area. The methylated allele in the PCR products was cut into 197/50
bp by the RsaI restriction enzyme. The second primer set (COBRA II; ERB-
CBR3; TAA ATT TGA GAT TGG GGT T, ERB-CBR4; AAA AAA TAA
TAC CTA AAC CCA) amplified a 170 bp fragment upstream from exon 1
(Fig. 1A). The amplified methylated allele was cut into 102/68 bp fragments
by the HhaI restriction enzyme. For both primer sets, amplification was
carried out by performing the following: a hot-start denaturation for 5 min at
95 °C, 40 PCR cycles (95 °C, 30 s; 50 °C, 30 s; 72 °C, 30 s), and a final
extension for 5 min at 72 °C. The PCRs were performed with 2 μl (100 ng)
bisulfite-treated genomic DNA in a 50 μl reaction volume containing 1× PCR
buffer, 2.5 mM dNTP mixture, 2 μM of each primer, and 2 units of Taq DNA
polymerase.
2.3. Identification of type of infiltrated inflammatory cell types in
intima
To identify the type of inflammatory cells invading the intimal layer, we
performed immunohistochemical staining (IHS) using cell specific mono-
clonal mouse anti-human antibodies (DakoCytomation, Inc., USA) for
plaque and non-plaque regions of AA and CCA in a male subject. CD3
antibody for T-cells, CD20 antibody for B-cells, and a CD68 antibody for
monocytes/macrophages were used for the immunohistochemical staining on
separate slides. The number of total and stained cells was counted from 3
different 400× fields in each stained slide.
2.4. Isolation of T-cells, B-cells, and monocytes/macrophages in
peripheral blood
CD3(+)-T cells and CD20(+)-B cells were positively isolated using anti-
CD3 and anti-CD20 antibody (mAb)-coupled magnetic cell-sorting (MACS)
microbeads (Miltenyl Biotech, Bergisch Gladbach, Germany). To isolate
CD68(+) cells, a suspension of leukocytes was initially generated by the
reaction with a CD68 monoclonal antibody (BD Pharmingen, USA). And
then, CD68(+)-monocytes/macrophages were separated using Rat Anti-
Mouse IgG2a+b Microbeads (Miltenyl Biotech, Bergisch Gladbach,
Germany). ER beta MSP evaluations were performed using DNA extracted
from total leukocytes, CD3(+), CD20(+), and CD68(+)cells.
2.5. Senescence in SMC and EC cell lines
All cultured SMC and EC cell lines were purchased from the Coriell
Institute. SMC and EC cell lines were maintained in M199 phenol red-free
media (Cellgro) containing 10% uninhibited FBS (GibcoBRL) for SMC or
15% inhibited FBS for EC, 2 mM L-glutamine, 1% penicillin/streptomycin,
0.02 mg/ml endothelial cell growth supplement (ECGS, BD Biosciences),
and 0.05 mg/ml heparin. Population doubling time (PDT) was calculated
using inoculated cell number, harvested cell number, and culture duration in
each passage. Cell lines were subcultured until they showed in-vitro
senescence. Senescence was defined as 0 or negative PDT, which means
no change or decreased number of cells from the inoculated cells in the
passage. In each subculture, one flask was split into three T75 or T25 flasks
for DNA and RNA extraction and for next subculture. The SW48 (ATCC)colon cancer cell line was used as a positive control for ERβ methylation
and expression level.
2.6. Changes in ERβ expression by demethylation and histone
deacetylation inhibition
5-aza-2′-deoxycytidine (DAC, Sigma) was used for demethylation and
trichostatin A (TSA, ICN) was used for histone deacetylation inhibition.
After an adaptation period of 24 h, four treatment conditions were used; 1)
Control, 2) DAC treatment (1 μM) daily for 3 days, 3) TSA treatment
(300 nM) for 20 h on the 3rd day, and 4) DAC/TSA treatment with the
combined protocol of DAC and TSA conditions. On the 4th day, cells were
harvested and RNA was extracted using TRIzol (Invitrogen), according to
the manufacturer's instructions.
RT-PCR was performed for evaluation of changes of ERβ expression
after DAC and/or TSA treatment. One μg of total RNA was reverse
transcribed using M-MuLV reverse transcriptase (Roche) according to the
manufacturer's instructions. RT-PCR for ERβ (ERB-RT1: 5′-TTCCCAG-
CAATGTCACTAACT-3′, ERB-RT2: 5′-CTCTTTGAACCTGGACCAGTA-
3′) amplified a 259 bp fragment of the N-terminal A/B region spanning one
intron of ERβ mRNA [12]. All PCR reactions were performed using 2 μl
of cDNA in a 50 μl total reaction volume containing 1.25 units Taq
polymerase, 1× PCR buffer (50 mM pH 8.0 Tris–Cl, 75 mM KCl),
1.5 mM MgCl2, 0.25 μl 2% gelatin, 10 mM dNTP, 2 μM of each primer,
and 5% in reaction volume of 1 M DMSO. Amplification was carried out
using denaturation for 5 min at 95 °C, hot-start, 37 cycles for ERβ (95 °C:
30 s, 51 °C: 30 s, 72 °C: 30 s), and final extension for 5 min at 72 °C.
Ten μl of PCR product was run on 2% agarose gel. PCR for GAPDH as a
control for RNA integrity (GAPDH1: 5′-TCCCATCACCATCTTCCAG-3′,
GAPDH2: 5′-ATGAGTCCTTCCACGATACC-3′) was also done with 2 μl
of cDNA for 23 cycles. All RT-PCR reactions included RT-controls where
the reverse transcriptase enzyme was omitted.
To quantitatively evaluate the expression differences among the four
treatment protocols, real time RT-PCR was performed in an ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster City, CA, USA)
using the same reverse transcribed cDNA. To evaluate ERβ expression, we
used the 20× ESR2 probe (Assay ID: Hs00230957_m1, Perkin-Elmer
Applied Biosystems), which amplified the exon boundary between exon 4
and 5. For an internal control, we evaluated GAPDH expression, by initially
using the GAPDH 307T probe (5′-CAGGAGCGAGATCC) labeled with 6-
FAM and MGBNFQ (TaqMan® MGB Probe 5000–6000 pmol, Part Number
4316034). Then, a 20× GAPDH primer–probe mixture was made with 20 μl
of GAPDH 307T-FAM-MGBNFQ probe mixed with 180 μl of GAPDH-284F
primer (5′-ATGGAATCCCATCACCATCTT , 100 μM), 180 μl of GAPDH-
340R primer (5′-CGCCCCACTTGATTTTGG, 100 μM), and 620 μl of DW.
The reaction mixture contained 10 μl of the TaqMan® Universal Master Mix
(Perkin-Elmer Applied Biosystems, Part No. 4304437), 1 μl of 20× primer–
probe mix, 7 μl of DW, and 2 μl of cDNA. Amplification was carried out by
the following steps: denaturation for 10 min at 95 °C and 40 PCR cycles
(95 °C, 30 s; 51 °C, 30 s; 72 °C, 30 s). ERβ and GAPDH real time RT-PCR
reactions for each sample were assayed in triplicate.
To analyze real time RT-PCR results, the average cycle number (CT) of
the reaction when it crossed a threshold value was determined for both the
ERβ and the GAPDH reactions. Differences in CT (ΔCT) between ERβ for
GAPDH were calculated by subtracting GAPDH ΔCT from the ERβ ΔCT.
The ratio of ERβ/GAPDH in each treatment condition was calculated as
2ΔCT. Finally, relative ERβ expression levels were determined by comparing
each E/G ratio in the DAC and/or the TSA treatment groups to the E/G
ratio of the control group.
2.7. Statistics
The average methylation levels in each type of tissues were compared
using ANOVA. Comparison of methylation levels between plaque and non-
plaque regions in the same vessels was assessed by Mann–Whitney tests.
All statistical analyses were performed using SPSS for Windows, version
11.0. P values were two-sided and considered significant p<0.05.
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3.1. ERβ methylation in atherosclerotic and cardiovascular
tissues
We used MSP to determine the presence and extent of ERβ
methylation. ERβ has a typical CpG island in its promoter/exon
1 region (Fig. 1A). Initial experiments showed that the SW48
colon cancer cell line has 100% methylation while peripheral
blood lymphocytes from a healthy donor had less than 5%
methylation. Mixing experiments indicated that MSP at 35
cycles measured methylation semi-quantitatively, with a linear
correlation between expected and measured methylation %
(Fig. 1B). We next studied 150 atherosclerotic and cardiovas-
cular tissue samples including IMA (N=14), AA (N=32), SV
(N=24), RA (N=36), CEA (N=19), and DCA (N=25). A
methylated band by MSP was detectable in all tested tissue
types (Fig. 1C), and the range of methylation was variable from
0 to 72.7% in atherosclerotic tissues and from 0 to 52.2% in
vascular tissues (Fig. 1D). In atherosclerotic tissues, DCA
samples showed the highest mean methylation level (28.7%,
p<0.01) among the tested tissue types, but CEA samples did
not show a similar increase in mean methylation level (11.9%).
Among the apparently normal vascular tissues, arterial sam-
ples (IMA; 6.7%, and AA; 10.1%) showed lower mean
methylation levels than venous samples (SV; 18.2%). In
particular, IMA showed the lowest mean methylation level
among the vascular tissue types (p<0.05) (Fig. 1D). The mean
methylation level in RA (14.4%) was in between arterial and
venous tissues.We also examined non-vascular tissues including
colon (N=14), oral mucosa (N=10), lung (N=9), and fibroblasts
(N=4). ERβ methylation was variable in the tested samples,
being lowest in fibroblasts (0%), followed by colon (0–11.5%),
lung (0–53%) and oral mucosa (0–53.6%). To verify the density
of ERβmethylation in selected samples, we performed bisulfite
sequencing on the methylated MSP products derived from two
DCA samples (V46 and V49). The methylation levels
determined by MSP were 63.5% in V46 and 51.2% in V49.
We cloned the PCR products and sequences from nine distinct
colonies of each sample were analyzed. The analyzed fragment
was 120 bp intervening primer sequences in whole 159 bp of
methylated MSP products. Ten CpG sites were contained in the
120 bp sequence (Fig. 2A). Almost all 10 CpG sites in the
analyzed sequences remained as CG, indicating dense methyla-
tion. In V46, only one among nine cloned alleles showed lack of
methylation at one CpG site. In V49, three among the nine
cloned alleles showed lack of methylation at two to three CpG
sites (Fig. 2B).
Methylation was also confirmed by using COBRA to
analyze two regions in the ERβ promoter. COBRA relies on
the bisulfite treatment of DNA. Both COBRA I and II primer
sets revealed evidence of ERβ methylation in cardiovascular
samples, but the quantitation was inconsistent in consecutive
experiments using the same vascular and control samples (data
not shown). These inconsistent results are likely due to PCR
bias, whereas a reaction will sometimes favor amplification of
the unmethylated alleles [13].3.2. ERβ methylation in paired plaque/non-plaque regions of
the same vessels
To determine whether the observed methylation is patient-
specific or lesion specific, we studied paired plaque/non-
plaque regions in segments of ascending aorta (AA),
common carotid artery (CCA), and femoral artery (FA) of
two patients. As seen in Fig. 3A and B, the plaque lesions
showed irregular thickening compared to the non-plaque
lesions in the same vessels, and the intimal layers of the
plaque lesions showed atherosclerotic thickening containing
variable numbers of macrophages, lymphocytes, and foamy
cells as well as smooth muscle cells and extracellular
matrix.
We performed 4 times of MSP to evaluate ERβ methy-
lation differences between atherosclerotic plaque and non-
plaque regions in these vessels (Fig. 3C and D). As
shown in Fig. 3E, plaque lesions had higher ERβ methy-
lation (average 5.0–23.3%) than non-plaque region (aver-
age 1.3–3.4%) in all studied vessels. The plaques showing
marked atherosclerotic changes (Fig. 3B, and data not
shown) had the most pronounced increases. For example,
the AA in the male patient (plaque; 16.4%±3.7% vs. non-
plaque; 5.9%±3.4%, p<0.01) and the CCA in the female
patient (plaque; 23.3%±5.3%, non-plaque; 3.4%±1.4%,
p<0.01) showed a high differential methylation. However,
the FA in patient 2, which had only slight hyperplasia
histologically, showed no ERβ methylation on MSP (Fig.
3D and E).
3.3. Identification of the infiltrating inflammatory cell types in
the intima
CD3 (+)-T cells (18.7 and 38.7% in plaque regions and 0
and 15.6% in non-plaque regions) and CD68 (+)-monocytes/
macrophages (13.5–17.1% in non-plaque regions and 17.1–
21.5% in plaque regions) were more frequently observed in
the plaque intima. However, CD20 (+)-B-cells were not
observed in the plaques or in the non-plaque intima. The
entire number of infiltrated inflammatory cells were 33.5–
59.7% of the total cell count in the plaque intima.
3.4. ER beta methylation levels in all leukocytes, CD3 (+),
CD20 (+), and CD68 (+) cells in the peripheral blood
Although ER beta methylation levels of all peripheral blood
leukocytes ranged from 4.3% in a 28-year-old man to 12.2%
in a 44 year-old man, and CD3 (+) and CD20 (+) cells showed
similar ER beta methylation levels. CD68 (+) cells had lower
ER beta methylation levels than all of the leukocytes together
or the other tested cell types. Finally, we evaluated ER beta
methylation levels of total leukocytes collected from 20
healthy and 20 subcortical infarction patients with ages
ranging from 51 to 74 years. Healthy subjects and stroke
patents had 2.7–8.9% ER beta methylation levels in total
leukocytes, although women showed higher methylation levels
than men.
Fig. 2. Bisulfite sequencing of MSP products of two DCA samples. (A) Schematic diagram of 10 CpG sites located in 120 bp intervening primer sequences of 159 bp
of methylated MSP fragment. Number in parentheses indicates start and last sequence number of the fragment in the ERβ promoter sequence AF191544. Closed line
indicates the location of backward and forward primers in the amplified MSP product. (B) Bisulfite sequencing results in two DCA samples (V46 and V49). Almost all
CpG sites in the amplified sequence were methylated in both samples. Horizontal line, 120 bp amplified fragment; vertical lines, individual CpG sites; closed circles,
methylated CpG sites; open circles, unmethylated CpG sites.
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To more precisely evaluate the aging-methylation link in
vascular tissues, we studied methylation in in-vitro senescence
of vascular smooth muscle cell (SMC) and endothelial cell (EC).
In-vitro senescence was studied in three SMC (AG11545b,
AG11546, AG11548) and three EC (AG10504b, AG10767,
AG10769) cell lines (Table 1). First harvest and split were
performed after overnight incubation of the received culture
flask (Passage 1). Thereafter, the cells were subcultured when
80% confluent (days 5–15) until senescence, typically occurring
at passage 6–12 from receipt.
Three of the six cell lines (EC AG10767, AG10769 and
SMC AG11548) showed a passage-dependent increase in ERβ
methylation. In SMC AG11548 cells, an increase in methyla-
tion was also observed at passage 5 (23.8%) (Fig. 4A). The
EC AG10767 cell line exhibited a step-wise increase of
methylation in advancing passages with 10.9% in passage 3,
23.5% in passage 4, 29.4% in passage 5, and 35.9% in
passage 6 (Fig. 4B). Passage-dependent methylation was alsoobserved in the AG10769 cell line, which increased from
4.0% at passage 3 to 9.1%, 10.4% and 14.5% at passages 6, 7,
and 8, respectively.
To confirm the extent of methylation, we performed bisulfite
sequencing on methylated MSP products from each passage of
EC AG10767 and SMC AG11548 cells. The methylation status
of ERβ after in-vitro senescence of SMC AG11548 cells
showed a progressive increase in density (Fig. 4A), such that in
the final passage, the methylation levels were similar to those
seen in the atherosclerotic samples (DCA). Thus, most of the
cloned alleles showed methylated C at 10 CpG sites (Fig. 4A).
Sequencing of EC AG10767 samples confirmed methylation at
the primer sites with much less extensive spreading of the
methylation compared to the SMC cell line.
3.6. Epigenetic control of ERβ expression
To study epigenetic control of ERβ expression directly,
the final passage of one SMC cell line (AG11548, PDL
34.4) and an early passage of one EC cell line (AG10504b,
Fig. 3. Microscopic findings and MSP results of plaque and non-plaque regions in the same blood vessel. (A) Microscopic findings of non-plaque region and
(B) plaque lesion in a representative vessel (ascending aorta of a 54-year-old male). The plaque lesion showed intimal thickening including macrophages, lymphocytes,
foamy cells, extracellular matrix, and smoothmuscle cells. Arrows indicate the intimal elastic lamina. (C)MSP results for ERβ in intimal layer of plaque and non-plaque
regions of different vessels from a 54-year-oldman and (D) a 54-year-oldwoman. The plaque lesions in each vessel showed amore prominentmethylated band than non-
plaque regions, except FA of 54-year-old woman, which showed no intimal thickening on microscopic observation. (E) Quantitation of differences in ERβmethylation
between plaque and non-plaque regions. All but one of the plaque lesions showed higher methylation levels than adjacent non-involved tissues. The plaque lesion in AA
of the man and CCA of the woman exhibited significantly higher methylation levels than the non-plaque regions (p<0.05). Man: 54-year-old man, Woman: a 54-year-
old woman, NP: non-plaque region, P: plaque region, AA: ascending aorta, CCA: common carotid artery, FA: femoral artery.
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DAC and the histone deacetylase inhibitor, TSA. The normal
SMC and EC cell lines showed good viability without changes
in cell attachment and an increase of floating cells after DAC
and TSA treatment. In both vascular cell lines, demethylation
and histone deacetylation inhibition significantly increased
ERβ expression (Fig. 5A and B).
Real time RT-PCR results quantitatively showed the
remarkable ERβ expression changes. DAC and/or TSA
treatment increased ERβ expression in both cell lines. In
particular, DAC treatment showed a marked increase in
expression when compared to TSA treatment. Furthermore,
in the SMC AG11548 cell line, the synergistic increase of
the expression was also observed when DAC and TSAtreatments were combined, a finding that is in concordance
with the RT-PCR results. These results indicate that ERβ
expression is partially under epigenetic control in senescing
vascular cells.
4. Discussion
Promoter-associated CpG island methylation is increasingly
recognized as one of the molecular changes that can be
observed in aging [2,3]. The ERα and β genes are important
candidate genes to study epigenetic changes in atherosclerosis
and vascular aging because ERα and β genes have classical
CpG islands in their promoter area and they potentially
modulate estrogenic cardiovascular protective effects. ERα
Table 1
Senescing vascular cell-lines studied
Cell-line Tissue
type
Donation
site
Gender Donor
age
PDL at
start
Methylation
changes at
senescence
AG11545b SMC Iliac a. M 25 24 No change
AG11546 SMC Iliac v. M 19 26 No change
AG11548 SMC Iliac a. M 17 30 Increase
AG10504b EC Iliac a. M 58 16 No change
AG10767 EC Iliac a. F 49 9 Increase
AG10769 EC Iliac a. F 21 8 Increase
SMC: vascular smooth muscle cell, EC: vascular endothelial cell, a: artery,
v: vein, PDL: population doubling level.
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reported in previous studies.
In this study, we demonstrated that epigenetic changes of
ERβ are prominent in atherosclerotic tissues (DCA). The
increased methylation in atherosclerotic lesions was confirmed
by comparing plaque/non-plaque regions in the same vessels.
Hypermethylation of ERβ was also observed in in-vitro
senescing vascular endothelial and smooth muscle cells. UnlikeFig. 4. MSP and bisulfite sequencing results of the cultured aortic smooth muscle and
senescence of SMCAG11548 and (B) EC AG10767 cells. P: passage number, DW: di
as a positive control, M: methylated alleles, UM: unmethylated alleles, %: methylatERα [8], EC also exhibited epigenetic changes in ERβ with
advancing passage. These findings confirm that epigenetic
changes characterize vascular aging and atherosclerosis. Thus,
epigenetic changes could start from early intimal changes such
as intimal hyperplasia, and could be also enhanced when the
early hyperplasia advanced to atherosclerotic changes. Epige-
netic changes in ERβ gene expression might be an important
biological mechanism involved in atherosclerosis and vascular
SMC and EC aging.
In addition to promoter hypermethylation, loss of global
genomic 5-methylcytosine content has also been described in
aging cells [14], neoplastic tissues [15], as well as advanced
human atherosclerotic lesions and in lesions of ApoE knock-
out mice [16]. Thus, the cancer methylation “paradox” of
global 5-methylcytosine loss and concurrent gains of promoter
methylation extends to vascular and atherosclerotic tissues.
However, the functional significance of hypomethylation in
cancer or atherosclerosis remains unclear.
ERβ methylation in vascular samples is clearly only partial.
This could be from a low degree of methylation in all cells, or a
high degree of methylation in only a few cells (epigeneticendothelial cells. (A) MSP and bisulfite sequencing results for ERβ after in-vitro
stilled water serving as a negative control, SW48: a colon cancer cell line serving
ed band intensity relative to methylated+unmethylated in each passage.
Fig. 5. Results of RT-PCR and real time RT-PCR for ERβ expression after demethylation and histone deacetylase inhibition. (A) RT-PCR and (B) real time RT-PCR
results from the SMCAG11548 cells (passage 5) and the (C) RT-PCR and (D) real-time RT-PCR results from the ECAG10504b cells (passage 1). ERβ expression was
significantly increased after DAC, TSA, and the combined DAC and TSA treatments. In particular, TSA treatment results showed that the synergistic effect on ERβ
expression was combined with DAC in EC AG10504b cells. Ctl: neither DAC nor TSA was added, DAC: addition of 5-aza-2′-deoxycytidine, TSA; addition of
trichostatin A, D+T: combined DAC and TSA treatments, ERb: estrogen receptor beta, DW: distilled water, used as a negative control, (+): Reverse transcription, (−):
reverse transcriptase was omitted in each sample as a negative control.
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concept of epigenetic mosaicism with focal areas of epigenetic
changes in vascular tissue. Thus, in DCA methylated allele
sequencing, almost all CpG sites were methylated, and a similar
pattern was observed in the final passage of a senescent SMC
cell line. Cells carrying these alleles would be expected to have
lost ERβ gene expression and to be physiologically distinct
from neighboring cells without such methylation. Athero-
sclerotic lesions usually develop in focal areas where the
mechanical forces are distinct such as in bifurcation area.
Eccentric intimal thickening in bifurcation and orifice of a
branch had been reported as a physiologic adaptation to
mechanical stresses to the vascular structures [17]. In addition,
a monoclonal hypothesis has been proposed to explain the focal
development of atherosclerotic lesions in these areas of
mechanical stress [17]. Combining all these observation, we
propose that age-related epigenetic alterations predispose a few
cells to the focal development of atherosclerotic lesions in a
background of predisposed vascular structures.
Different ERβ methylation levels among tested vascular
tissue types suggest different degrees of susceptibility to
epigenetic changes. The arterial system, IMA and AA, showed
lower levels of methylation than the venous system, SV. Marked
differences in ERβ epigenetic changes between IMA and SV
support the clinical experience for the superiority of IMA as a
coronary artery bypass grafting conduit. In previous studies to
evaluate estrogen replacement therapy, different benefits were
observed in coronary heart disease and ischemic cerebrovas-
cular disease [18,19]. Interestingly, different methylation levels
between CEA and DCA suggest potentially different mechan-
isms for these two atherosclerotic lesions.
The total amount of ER beta methylation in intimal regions
includes the methylation of the infiltrated inflammatory cells aswell as the smooth muscle cells. However, all peripheral blood
leukocytes together had only a 2.7 to 8.9% methylation in the
healthy subjects as well as in the subcortical stroke patients.
Predominantly infiltrating CD3 (+) cells and CD68 (+) cells in
plaque and non-plaque intimas had similar or lower levels of the
ER beta methylation compared to the methylation in the total
leukocyte population. Furthermore, activation does not influ-
ence the genomic DNA methylation status of CD3 (+)-T-blast
cells [20]. Therefore, the CD3 (+) and CD68 (+) cells infil-
trating the intima might only influence the basal level of ER
beta methylation in both plaques and non-plaque regions.
Individual differences in susceptibility were another char-
acteristic of the observed epigenetic changes. A variable range
of ERβ methylation has been observed in all types of vascular
tissues, and passage-dependent methylation was only seen in
three among six tested cell lines. Potential explanations for
these differences include genetic susceptibility to methylation,
lifestyle or exposure factors (including diet), and the random
nature of this event.
Demethylation and histone deacetylation inhibition are
known methods to augment the expression of silenced genes
[21]. In normal SMC and EC, demethylation and histone
deacetylation inhibition increased the expression of ERβ
supporting the concept of epigenetic regulation of this gene.
Remarkably, DAC and/or TSA appeared to have little toxicity in
these cell lines, which is very different from cancer cell lines. A
similar phenomenon has been observed in senescing fibroblasts
[22]. Modifying epigenetic status in vascular tissues deserves
investigation as a prevention method for the development and
progression of atherosclerosis. In fact, it is interesting to
speculate that the lack of efficacy of estrogen as a cardio-
protector in the Women's Health Initiative study may be related
in part to age-related epigenetic silencing of estrogen receptors
80 J. Kim et al. / Biochimica et Biophysica Acta 1772 (2007) 72–80in critical cells, which would then be non-responsive to
hormone replacement therapy [23]. If this were true, combined
epigenetic therapy and hormone replacement therapy could
potentially overcome this barrier.
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